Aptamino is a biotechnology company that enables oral antibody delivery utilizing protein design.
Aptamino has raised $8.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in April 2026.
Aptamino is headquartered in New York, United States.
Aptamino is a biotechnology company that enables oral antibody delivery utilizing protein design.
Aptamino is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Aptamino — Funding & Investors." VCBacked, April 3, 2026, https://www.vcbacked.co/company/aptamino. Accessed August 16, 2026.
VCBacked. (2026). Aptamino — Funding & Investors. Retrieved August 16, 2026, from https://www.vcbacked.co/company/aptamino
{{cite web |title=Aptamino — Funding & Investors |url=https://www.vcbacked.co/company/aptamino |website=VCBacked |access-date=August 16, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated